Cargando…
Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021
Ejemplares similares
-
Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022
por: Halasa, Natasha B., et al.
Publicado: (2022) -
Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021
por: Olson, Samantha M., et al.
Publicado: (2021) -
Tachyarrhythmias During Hospitalization for COVID‐19 or Multisystem Inflammatory Syndrome in Children and Adolescents
por: Dionne, Audrey, et al.
Publicado: (2022) -
Risk factors for health impairments in children after hospitalization for acute COVID-19 or MIS-C
por: Maddux, Aline B., et al.
Publicado: (2023) -
Effectiveness of Maternal mRNA COVID-19 Vaccination During Pregnancy Against COVID-19–Associated Hospitalizations in Infants Aged <6 Months During SARS-CoV-2 Omicron Predominance — 20 States, March 9, 2022–May 31, 2023
por: Simeone, Regina M., et al.
Publicado: (2023)